HAON Life Sciences

What HAON Life Sciences does

HAON Life Sciences is a Dublin, Ireland-based private biotechnology company founded in 2022 that is developing advanced cell therapies through its core offering, the CanVas Cell Therapy Platform. The company's primary research focus is Hypoxic-Ischemic Encephalopathy (HIE), a devastating pediatric condition, positioning HAON in a niche area of pediatric regenerative medicine where it aims to translate cell-based therapeutic interventions into treatments for life-threatening conditions. The platform is described as a domain-specialized cell therapy architecture intended to enable the development and delivery of advanced therapeutic interventions to healthcare providers, biotech companies, and research institutions.

The company operates at a very early stage, with 1–10 employees and Founder & Executive Chairman Mark O'Neill providing the disclosed leadership. Its primary disclosed capital event is an $11,711,486 funding round completed on 2025-04-09 led by the Disruptive Technologies Innovation Fund, which represents the company's main financial backbone for advancing R&D and platform development. HAON does not have a publicly disclosed pricing model, named customers, or commercial revenue, and its go-to-market is not articulated beyond a generic "Contact Us" email channel ([email protected]).

The business model appears to be a long-horizon biotech R&D play — developing cell therapy IP and platform capabilities with the intent of ultimately commercializing therapeutic products or licensing the CanVas platform to larger biotech and pharmaceutical partners. Pricing details, revenue mechanics, certifications, patents, trademarks, and partnership arrangements are not disclosed in the available data, reflecting both the early-stage nature of the company and the limited public information footprint.

Name

HAON Life Sciences

Legal name

HAON

Website

https://haonco.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

HAON Life Sciences is a Dublin-based early-stage biotech founded in 2022 developing the CanVas Cell Therapy Platform, with primary research targeting Hypoxic-Ischemic Encephalopathy (HIE) in pediatric patients. It serves healthcare providers, biotech firms, and research institutions.

Ownership category

akta.pro rank

Product category

Cell Therapy / Regenerative Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Cell therapy platform
• Regenerative medicine
• Pediatric therapeutics
• Cell-based treatments
• Biotechnology research

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Core offering

HAON Life Sciences develops advanced cell therapies using its proprietary CanVas Cell Therapy Platform, with primary research targeting Hypoxic-Ischemic Encephalopathy (HIE), a devastating pediatric condition. The platform is designed to enable the development and delivery of life-changing, advanced cell-based therapeutic interventions for patients with life-threatening conditions.

Product overview

HAON Life Sciences offers the CanVas Cell Therapy Platform as its core product offering. This platform is designed to unlock life-changing medical treatments by enabling the development and delivery of advanced cell-based therapeutic interventions.

Differentiator

Problem solved

Functional benefit

Products and services

• CanVas Cell Therapy Platform

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• ReNeuron Group: UK-based clinical-stage cell therapy developer focused on neural stem cell platforms for stroke and retinal disease. Most directly comparable to HAON as a small, platform-based cell therapy company targeting neurological indications with a single enabling technology.
• Athersys: US clinical-stage company developing MultiStem, a proprietary adult stem cell platform applied across neurological and inflammatory indications including stroke. Comparable as a platform cell therapy company pursuing neurological indications with a single enabling technology.
• BrainStorm Cell Therapeutics: Cell therapy developer of NurOwn, an autologous MSC-based therapy for ALS and other neurodegenerative diseases. Directly comparable to HAON as a focused cell therapy company targeting neurological disease with a specialized platform.
• Stemedica Cell Technologies: Developer of allogeneic adult stem cell therapies with applications in ischemic and neurological conditions. Comparable to HAON in modality (stem cell therapy), neurological focus, and platform-based development model.
• SanBio: Japan/US regenerative medicine company developing cell therapies for neurological conditions including stroke and traumatic brain injury. Comparable to HAON as a focused neurological cell therapy developer with a specialized platform approach.
• Capricor Therapeutics: Clinical-stage biotech developing cell therapy (CAP-1002) for Duchenne muscular dystrophy and other rare diseases. Comparable as a small-cap, platform-based cell therapy company targeting serious diseases with limited treatment options.
• Novadip Biosciences: Belgium-based clinical-stage cell therapy company developing autologous cell-based therapies for tissue regeneration. Comparable to HAON as a European small-cap cell therapy platform developer applying specialized enabling technology to serious conditions.

Broad incumbents

• Mesoblast: Established commercial-stage cell therapy company with a mesenchymal lineage platform across multiple indications including inflammatory and cardiovascular diseases. Broader incumbent comparable in modality (cell therapy) and platform-based development but operates at significantly larger scale than HAON.
• Pluristem Therapeutics: Clinical-stage cell therapy company developing placenta-derived cell therapies across multiple indications. Comparable as a platform cell therapy company but operates at broader scale and across more indications than HAON's focused HIE approach.

Others

• Avectas: Ireland-based cell engineering technology company developing non-viral delivery platforms for advanced cell therapies. Comparable as an enabling-technology company in the cell therapy space, particularly relevant given shared Irish ecosystem and overlap with HAON's cell therapy enabling focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/haon-life-science

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HAON Life Sciences